The Weekly Roundup: April 14-18

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Rosacea: Progress, Challenges, and the Road Ahead

Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches.

Systemic Therapies Offer New Hope for Severe AD

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

Shea Butter-Based Emollient is Effective for Pediatric Erythema on Diapered Skin

The novel formulation was compared to a petrolatum-based diaper and was found to be just as effective for irritation and redness.

HyBryte Achieves 75% Treatment Success by Week 18 in Ongoing CTCL Trial

Interim FDA-funded study results show HyBryte delivers rapid, sustained response and strong safety in early-stage CTCL patients.

V-FC Handpiece Combines RF and Vacuum for Facial Contouring

Skin laxity improved by 34% with a moderate rate of improvement in female participants.

Women with Psoriasis More Likely to Discontinue Biologics Than Men, Study Finds

A recent study reveals that women with psoriasis are more likely to discontinue biologic treatments, including IL-17 and IL-23 inhibitors, due to adverse events and treatment dissatisfaction.

Beyond Melasma: Systemic Causes of Facial Hyperpigmentation

Facial hyperpigmentation may signal systemic disease. Dermatologists must assess beyond melasma to ensure timely, accurate diagnosis and care.

Nail-Picking and Biting: More Than Bad Habits

In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling.

Evommune Advances EVO756 Into Global Phase 2b Trial for Chronic Spontaneous Urticaria

Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.

Attovia Closes $90 Million Series C Financing for ATTOBODY Programs

The funds will target programs for chronic pruritus, atopic dermatitis, and other inflammatory skin conditions.

Topical Antioxidants Combined with Phototherapy Effective for Vitiligo Management

Corticosteroids, calcineurin inhibitors, and fractional CO2 laser were also effective in achieving high levels of repigmentation.

New Study Sheds Light on Vitiligo-CHD Association

Phototherapy, commonly used for vitiligo, might help reduce cardiovascular risk through anti-inflammatory effects.

Compound Heparin Sodium Allantoin Gel Can Treat Rosacea and Improve Skin Barrier

Improvements in hydration, erythema, itching, and burning were observed after 12 weeks of treatment for papulopustular rosacea.

Journal Digest: April 16

This review of the latest dermatologic studies includes insights into dermatologic associations in patients with Crohn's disease, the prevalence of tinea pedis in pediatric populations, and more.

Nonsteroidal Tapinarof Cream Provides Long-Lasting AD Relief

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

Immunosuppressed Patients Respond Well to Electrochemotherapy for Skin Cancer

High response rates and no systemic toxicity in multiple nonmelanoma skin tumors were observed in this vulnerable patient population.

Shawn Kwatra, MD, Endowed as Dr. Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine

Colleagues, mentors, and patients gathered to discuss Kwatra’s immense achievements throughout his career and the milestones that led to his endowed position.

Genetics Suggest New Vitiligo Treatment Path

Genetic proxies for PCSK9 inhibition were consistently associated with reduced vitiligo risk across 2 biobanks.

Platelet-Rich Plasma is a Potential Therapy for Lichen Planus Pigmentosus

The pilot study showed notable decreases in mean melanin index after 3 sessions of PRP injections.

One-Stop Shop: RAD Offers Comprehensive Insights Into AD Diagnosis, Treatment, and Research

Raj Chovatiya, MD, PhD, MSCI, reviews the benefits of Revolutionizing Atopic Dermatitis as a disease-specific conference.

Expert Insights From AAD 2025

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

32.5% Decrease in Basal Cell Carcinoma Surgeries Reported Due to COVID-19 Pandemic

Additionally, BCC surgery candidates have been older with more comorbidities since the pandemic began.

Larry Eichenfield, MD: Icotrokinra Demonstrates Promising Results for Adolescents With Moderate to Severe Plaque Psoriasis

Eichenfield discusses high skin clearance and safety in teens with psoriasis, per new ICONIC-LEAD phase 3 data.

Screening for BDD Crucial in Aesthetic Dermatology

Patients undergoing plastic surgery have the highest prevalence of BDD at 24%.

How Anastasia Georgievskaya and SkinGPT Are Addressing Gaps in the Dermatology Industry

Haut.AI’s new tool promotes inclusive and realistic conversations on the power of skincare products, according to the CEO.

Hope on the Horizon: FDA to Weigh in on Dupilumab for CSU

Having multiple therapeutic options would allow clinicians to tailor treatment and offer hope to patients who don't respond initially.

Channel Therapeutics and Pelthos Therapeutics to Merge to Accelerate Launch of Zelsuvmi for Molluscum Contagiosum

Pelthos and Channel Therapeutics will merge to form a new publicly traded entity focused on commercializing the first at-home treatment for molluscum.

Retirement Plans 101: What Dermatologists Need to Know

QRPs are key to dermatologists' retirement plans—learn the benefits, drawbacks, and how to choose the best strategy for your financial goals.

Art Meets Medicine in Bold New AAD Showcase

Spearheaded by John Zampella, MD, FAAD, and Mitchell Hanson, the project highlights how art can foster community and empathy in dermatology.

FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Gene Expression Profile Testing Offers Clinicians a Path to Safely Avoid SLNB in Low-Risk Melanoma Patients

New prospective data from the DECIDE study reinforce the role of the 31-GEP test in clinical decision-making.

Immunocompromised Patients with Actinic Keratosis Respond Well to LED Daylight Photodynamic Combination Therapy

Solid organ transplant recipients saw a 79.6% decrease in lesions 12 weeks after the treatment sessions.

The Hidden Complexity of Reporting AEs

Trials often exclude high-risk patients, limiting the real-world relevance of their safety findings.

Treating Rosacea and Other Concerns with Generative Skin’s Ingredient Library

As a patient with rosacea herself, Anastasia Georgievskaya highlights the innovation of Generative Skin in patient education.